Phase II Study of the Novel Peptide-Nucleic Acid OHR118 in the Management of Cancer-Related Anorexia/Cachexia

OHR118 again mediated statistically significant improvements in anorexia, dyspepsia, strength, and depression in this trial, consonant with the previous AIDS trial results.